Biotech and Pharmaceuticals Pharmaceuticals

  • Mark Bertolini, CEO of Aetna.

    People may be worried that health-care costs will increase and become a trend, Aetna's CEO said he's not.

  • Screen shot of Marc Beer on CNBC

    A nasty Wall Street divorce has touched two biotech CEOs and appears to have moved their company stocks down over drug use allegations.

  • Novartis' precision M&A' plan: CEO

    We are focusing on three big divisions in the next five years - pharmaceuticals, generics and eye care., says Joe Jimenez, Novartis CEO, explaining how Novartis plans to benefit from partnering with other big pharma companies.

  • Novartis CEO on big pharma pipeline

    We are focusing on innovation, says Joe Jimenez, Novartis CEO, discussing the company's growth prospects and the top three drugs driving sales.

  • Shares of Sanofi tumbled around 7.4 percent early on Tuesday after the French drugmaker reported weaker-than-expected Q3 sales.

  • obesity over weight health

    With some 84 million people in the U.S. struggling with obesity, investing in obesity stocks has become a Wall Street trend.

  • Amanda Smith, graduate student from the University of Utah, holds a container with test material in a sealed lab with a non-infective forum of the Ebola virus to help discover a drug that is effective against a part of Ebola that is vulnerable to drugs, on October 14, 2014 in Salt Lake City, Utah.

    Researchers say they have developed a test that can diagnose Ebola within 30 minutes, the BBC reports.

  • Checkup on big pharma

    Barbara Ryan, FTI Consulting, breaks down the numbers on Merck's quarterly results as the company appears to be reaping the rewards of R&D. Also a look ahead to Pfizer's earnings

  • Drugmakers want indemnity

    Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.

  • Eli Lilly earnings plunged, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year forecast.

  • Inside Eli Lilly's earnings: CEO

    John Lechleiter, Eli Lilly CEO, crunches the numbers on his company's quarterly results and explains how a strong dollar is impacting global sales.

  • Paulson hedge fund urges Allergan bid for Shire

    Paulson & Co, a shareholder in Allergan, urged the Botox maker to launch a bid for Shire after AbbVie walked away from a takeover, CNBC's Catherine Boyle reports.

  • Valeant's bid for Allergan

    Michael Pearson, Valeant Pharmaceuticals CEO, shares his thoughts on allegations Allergan released false and misleading information.

  • Valiant effort by Valeant, Q3 beats estimates

    Michael Pearson, Valeant Pharmaceuticals CEO, breaks down the company's quarterly numbers and provides an outlook on future growth.

  • Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.

  • Center for Disease Control (CDC) head Dr. Thomas Frieden speaks duing a briefing on the Dallas Ebola response at the CDC Headquarters on October 13, 2014 in Atlanta, Georgia.

    Three people had contact with the latest Ebola patient before she was isolated, said Dr. Tom Frieden. One texas Ebola patient will be moved to Emory.

  • Italian Air Force soldiers attend a military exercise preparing to help people infected with the Ebola virus at the Pratica di Mare Air Base, near Rome, on September 24, 2014.

    The Ebola outbreak rages on. But there is no vaccine for this deadly disease, raising questions if the world is prepared for an epidemic.

  • Should AbbVie still pursue Shire?

    Cole Smead, portfolio manager at Smead Capital Management, says that AbbVie's acquisition of Shire would be "very accretive" to shareholders and that the tax inversion part is not that important.

  • AbbVie reconsidering Shire deal

    AbbVie has announced that it is reconsidering its acquisition of the U.K.'s Shire following the U.S. crackdown on tax inversion deals, CNBC's Catherine Boyle reports.

  • GW Pharma: Focused on epilepsy

    GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.